Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 2/20 | 0.54 |
| ▸ | POLB | P06746 | 3/20 | 0.49 |
| ▸ | NPC1 | O15118 | 3/20 | 0.49 |
| ▸ | RAB9A | P51151 | 3/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | PLK1 | P53350 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5327317 | 0.84 | KDM4E (0.60) | NPC1RAB9ASMN1; SMN2MEN1KMT2A | |
| SCHEMBL3846947 | 0.81 | MAPT (0.53) | ACACBNPC1RAB9ASMN1; SMN2L3MBTL1 | |
| SCHEMBL28180587 | 0.79 | POLB (0.53) | POLBNPC1RAB9ATDP1SMN1; SMN2 | |
| SCHEMBL4171208 | 0.78 | ESR1 (0.59) | MEN1KMT2ALMNAHPGDALDH1A1 | |
| SCHEMBL27461036 | 0.78 | CYP3A4 (0.50) | ACACBMAPK1EPHX2MEN1KMT2A | |
| SCHEMBL5948337 | 0.78 | CYP3A4 (0.67) | POLBNPC1RAB9ASMN1; SMN2MAPK1 | |
| SCHEMBL12561575 | 0.77 | NQO1 (0.61) | POLBNPC1RAB9ATDP1SMN1; SMN2 | |
| SCHEMBL9718295 | 0.77 | KDM4E (0.57) | SMN1; SMN2MEN1KMT2ALMNAHPGD | |
| SCHEMBL28794058 | 0.77 | CYP2C9 (0.49) | ACACBSMN1; SMN2MAPK1MEN1KMT2A | |
| SCHEMBL16041240 | 0.77 | ALDH1A1 (0.49) | ACACBPOLBNPC1RAB9AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105377834-B | The derivative of dolastatin 10 and Ao Li statins | 皮埃尔法布雷医药公司 | 2018-04-20 | — | — | CN | disclosed |
| CN-106470708-A | Antibody-drug-conjugates and their use for the treatment of cancer | 皮埃尔法布雷医药公司 | 2017-03-01 | — | — | CN | disclosed |
| CN-106456800-A | IGF-1R antibody-drug-conjugates and uses thereof for the treatment of cancer | 皮埃尔法布雷医药公司 | 2017-02-22 | — | — | CN | disclosed |
| US-20090181961-A1 | NOVEL MEDICAMENTS FOR THE TREATMENT OF RESPIRATORY DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-07-16 | — | — | US | disclosed |
| US-20080167298-A1 | MEDICAMENTS FOR THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2008-07-10 | — | — | US | disclosed |
| US-20050272726-A1 | Novel medicaments for the treatment of respiratory diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-12-08 | — | — | US | disclosed |
| US-20050256115-A1 | Aerosol formulation for the inhalation of beta-agonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-11-17 | — | — | US | disclosed |
| US-20050239778-A1 | Novel medicament combinations for the treatment of respiratory diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH | 2005-10-27 | — | — | US | disclosed |
| US-20050222144-A1 | Medicaments for the treatment of chronic obstructive pulmonary disease | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-10-06 | — | — | US | disclosed |
| US-20040147513-A1 | New medicaments for the treatment of chronic obstructive pulmonary disease | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080167298-A1 | MEDICAMENTS FOR THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, SLC26A4, CHRM1 | ACACB 1967/4885POLB 3035/4885NPC1 50/4885 |
| US-20050256115-A1 | Aerosol formulation for the inhalation of beta-agonists | ADRB1, ADRB2, ADRB3 | ACACB 2328/4885POLB 1918/4885NPC1 1914/4885 |
| US-20090181961-A1 | NOVEL MEDICAMENTS FOR THE TREATMENT OF RESPIRATORY DISEASES | MRGPRX2, MRGPRX1, CFTR | ACACB 3213/4885POLB 3158/4885NPC1 754/4885 |
| US-20050222144-A1 | Medicaments for the treatment of chronic obstructive pulmonary disease | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, SLC26A4, CHRM1 | ACACB 1990/4885POLB 2999/4885NPC1 53/4885 |
| US-20050272726-A1 | Novel medicaments for the treatment of respiratory diseases | MRGPRX2, MRGPRX1, CFTR | ACACB 3213/4885POLB 3158/4885NPC1 754/4885 |
| US-20040147513-A1 | New medicaments for the treatment of chronic obstructive pulmonary disease | CLIC1, OTC, SLC10A1 | ACACB 1255/4885POLB 2583/4885NPC1 29/4885 |
| US-20050239778-A1 | Novel medicament combinations for the treatment of respiratory diseases | MRGPRX2, MRGPRX1, MTNR1B | ACACB 3033/4885POLB 4066/4885NPC1 1010/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.